These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23073049)

  • 1. Novel agents in invasive urothelial cancer.
    Balar AV; Milowsky MI
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):504-16. PubMed ID: 23073049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
    Mitra AP; Datar RH; Cote RJ
    J Clin Oncol; 2006 Dec; 24(35):5552-64. PubMed ID: 17158541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma.
    Paner GP; Ro JY; Wojcik EM; Venkataraman G; Datta MW; Amin MB
    Am J Surg Pathol; 2007 Sep; 31(9):1420-9. PubMed ID: 17721199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma.
    Ayala de la Peña F; Kanasaki K; Kanasaki M; Tangirala N; Maeda G; Kalluri R
    J Biol Chem; 2011 Jun; 286(23):20778-87. PubMed ID: 21388952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.
    Mugabe C; Matsui Y; So AI; Gleave ME; Baker JH; Minchinton AI; Manisali I; Liggins R; Brooks DE; Burt HM
    Clin Cancer Res; 2011 May; 17(9):2788-98. PubMed ID: 21357680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the expression pattern of p16, pRb and p53 and the response to intravesical bacillus Calmette-Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder.
    Sato M; Yanai H; Morito T; Oda W; Shin-no Y; Yamadori I; Tshushima T; Yoshino T
    Pathol Int; 2011 Aug; 61(8):456-60. PubMed ID: 21790859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-betaRII, BAX, IGFIIR, caspase-5, hMSH3 and hMSH6 alterations are not associated with microsatellite instability or p53 mutations in invasive urothelial carcinoma of the urinary bladder.
    Saetta AA; Korkolopoulou P; Karlou M; Levidou G; Goudopoulou A; Thymara I; Stamatelli A; Tzivras M; Michalopoulos NV; Thomas-Tsagli E; Patsouris E
    Pathology; 2007 Aug; 39(4):425-32. PubMed ID: 17676485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways of urothelial development and bladder tumorigenesis.
    Castillo-Martin M; Domingo-Domenech J; Karni-Schmidt O; Matos T; Cordon-Cardo C
    Urol Oncol; 2010; 28(4):401-8. PubMed ID: 20610278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of vascular endothelial growth factors A, C and D as indicators of lymphangiogenesis and angiogenesis in invasive and non-invasive urothelial carcinoma bladder.
    Khadim MT; Ahmed SA; Khan FA; Ikram A; Shaikh SY
    J Pak Med Assoc; 2015 Aug; 65(8):851-6. PubMed ID: 26228330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.
    Chang N; Lee HW; Lim JE; Jeong DE; Song HJ; Kim S; Nam DH; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
    Oncotarget; 2016 Aug; 7(32):51626-51639. PubMed ID: 27438149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA; Zhu F; Herr HW
    BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
    Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
    Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa.
    Palmeira C; Lameiras C; Amaro T; Lima L; Koch A; Lopes C; Oliveira PA; Santos L
    Urol Oncol; 2011; 29(2):205-11. PubMed ID: 19854077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder cancer: molecular determinants of personalized therapy.
    Lopez-Beltran A; Santoni M; Massari F; Ciccarese C; Tortora G; Cheng L; Moch H; Scarpelli M; Reymundo C; Montironi R
    Curr Drug Targets; 2015; 16(2):115-24. PubMed ID: 25654736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathogenesis of urothelial bladder cancer.
    Theodorescu D
    Histol Histopathol; 2003 Jan; 18(1):259-74. PubMed ID: 12507305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of urinary bladder cancer.
    Al Hussain TO; Akhtar M
    Adv Anat Pathol; 2013 Jan; 20(1):53-60. PubMed ID: 23232572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.